Report cover image

Global Amyloidosis Therapeutics Industry Growth and Trends Forecast to 2031

Publisher APO Research, Inc.
Published Oct 20, 2025
Length 100 Pages
SKU # APRC20548713

Description

Summary

According to APO Research, The global Amyloidosis Therapeutics market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Amyloidosis Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Amyloidosis Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Amyloidosis Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global manufacturers of Amyloidosis Therapeutics include Pfizer Inc., GlaxoSmithKline Plc, SOM Innovation Biotech SL, Prothena Corporation Plc, ProteoTech, Inc., Onyx Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc. and Celgene Corporation, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Amyloidosis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyloidosis Therapeutics.
The Amyloidosis Therapeutics market size, estimations, and forecasts are provided in terms of sales volume (k units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Amyloidosis Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Amyloidosis Therapeutics Segment by Company

Pfizer Inc.
GlaxoSmithKline Plc
SOM Innovation Biotech SL
Prothena Corporation Plc
ProteoTech, Inc.
Onyx Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Isis Pharmaceuticals, Inc.
Celgene Corporation
Bsim2
Bellus Health Inc.
Arcturus Therapeutics, Inc
Alnylam Pharmaceuticals, Inc.
Amyloidosis Therapeutics Segment by Type

Canakinumab
CAEL-101
ALN-TTRsc02
ALN-ANG
AG-10
Others
Amyloidosis Therapeutics Segment by Application

ATTR Amyloidoses
AL Amyloidosis
AA Amyloidoses
Others
Amyloidosis Therapeutics Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyloidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Amyloidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyloidosis Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Amyloidosis Therapeutics manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Sales, revenue of Amyloidosis Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.
Chapter 13: Concluding Insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

100 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Amyloidosis Therapeutics Market Size Estimates and Forecasts (2020-2031)
1.2.2 Global Amyloidosis Therapeutics Sales Estimates and Forecasts (2020-2031)
1.3 Amyloidosis Therapeutics Market by Type
1.3.1 Canakinumab
1.3.2 CAEL-101
1.3.3 ALN-TTRsc02
1.3.4 ALN-ANG
1.3.5 AG-10
1.3.6 Others
1.4 Global Amyloidosis Therapeutics Market Size by Type
1.4.1 Global Amyloidosis Therapeutics Market Size Overview by Type (2020-2031)
1.4.2 Global Amyloidosis Therapeutics Historic Market Size Review by Type (2020-2025)
1.4.3 Global Amyloidosis Therapeutics Forecasted Market Size by Type (2026-2031)
1.5 Key Regions Market Size by Type
1.5.1 North America Amyloidosis Therapeutics Sales Breakdown by Type (2020-2025)
1.5.2 Europe Amyloidosis Therapeutics Sales Breakdown by Type (2020-2025)
1.5.3 Asia-Pacific Amyloidosis Therapeutics Sales Breakdown by Type (2020-2025)
1.5.4 South America Amyloidosis Therapeutics Sales Breakdown by Type (2020-2025)
1.5.5 Middle East and Africa Amyloidosis Therapeutics Sales Breakdown by Type (2020-2025)
2 Global Market Dynamics
2.1 Amyloidosis Therapeutics Industry Trends
2.2 Amyloidosis Therapeutics Industry Drivers
2.3 Amyloidosis Therapeutics Industry Opportunities and Challenges
2.4 Amyloidosis Therapeutics Industry Restraints
3 Market Competitive Landscape by Company
3.1 Global Top Players by Amyloidosis Therapeutics Revenue (2020-2025)
3.2 Global Top Players by Amyloidosis Therapeutics Sales (2020-2025)
3.3 Global Top Players by Amyloidosis Therapeutics Price (2020-2025)
3.4 Global Amyloidosis Therapeutics Industry Company Ranking, 2023 VS 2024 VS 2025
3.5 Global Amyloidosis Therapeutics Major Company Production Sites & Headquarters
3.6 Global Amyloidosis Therapeutics Company, Product Type & Application
3.7 Global Amyloidosis Therapeutics Company Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Amyloidosis Therapeutics Market CR5 and HHI
3.8.2 Global Top 5 and 10 Amyloidosis Therapeutics Players Market Share by Revenue in 2024
3.8.3 2023 Amyloidosis Therapeutics Tier 1, Tier 2, and Tier 3
4 Amyloidosis Therapeutics Regional Status and Outlook
4.1 Global Amyloidosis Therapeutics Market Size and CAGR by Region: 2020 VS 2024 VS 2031
4.2 Global Amyloidosis Therapeutics Historic Market Size by Region
4.2.1 Global Amyloidosis Therapeutics Sales in Volume by Region (2020-2025)
4.2.2 Global Amyloidosis Therapeutics Sales in Value by Region (2020-2025)
4.2.3 Global Amyloidosis Therapeutics Sales (Volume & Value), Price and Gross Margin (2020-2025)
4.3 Global Amyloidosis Therapeutics Forecasted Market Size by Region
4.3.1 Global Amyloidosis Therapeutics Sales in Volume by Region (2026-2031)
4.3.2 Global Amyloidosis Therapeutics Sales in Value by Region (2026-2031)
4.3.3 Global Amyloidosis Therapeutics Sales (Volume & Value), Price and Gross Margin (2026-2031)
5 Amyloidosis Therapeutics by Application
5.1 Amyloidosis Therapeutics Market by Application
5.1.1 ATTR Amyloidoses
5.1.2 AL Amyloidosis
5.1.3 AA Amyloidoses
5.1.4 Others
5.2 Global Amyloidosis Therapeutics Market Size by Application
5.2.1 Global Amyloidosis Therapeutics Market Size Overview by Application (2020-2031)
5.2.2 Global Amyloidosis Therapeutics Historic Market Size Review by Application (2020-2025)
5.2.3 Global Amyloidosis Therapeutics Forecasted Market Size by Application (2026-2031)
5.3 Key Regions Market Size by Application
5.3.1 North America Amyloidosis Therapeutics Sales Breakdown by Application (2020-2025)
5.3.2 Europe Amyloidosis Therapeutics Sales Breakdown by Application (2020-2025)
5.3.3 Asia-Pacific Amyloidosis Therapeutics Sales Breakdown by Application (2020-2025)
5.3.4 South America Amyloidosis Therapeutics Sales Breakdown by Application (2020-2025)
5.3.5 Middle East and Africa Amyloidosis Therapeutics Sales Breakdown by Application (2020-2025)
6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Pfizer Inc. Comapny Information
6.1.2 Pfizer Inc. Business Overview
6.1.3 Pfizer Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Pfizer Inc. Amyloidosis Therapeutics Product Portfolio
6.1.5 Pfizer Inc. Recent Developments
6.2 GlaxoSmithKline Plc
6.2.1 GlaxoSmithKline Plc Comapny Information
6.2.2 GlaxoSmithKline Plc Business Overview
6.2.3 GlaxoSmithKline Plc Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.2.4 GlaxoSmithKline Plc Amyloidosis Therapeutics Product Portfolio
6.2.5 GlaxoSmithKline Plc Recent Developments
6.3 SOM Innovation Biotech SL
6.3.1 SOM Innovation Biotech SL Comapny Information
6.3.2 SOM Innovation Biotech SL Business Overview
6.3.3 SOM Innovation Biotech SL Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.3.4 SOM Innovation Biotech SL Amyloidosis Therapeutics Product Portfolio
6.3.5 SOM Innovation Biotech SL Recent Developments
6.4 Prothena Corporation Plc
6.4.1 Prothena Corporation Plc Comapny Information
6.4.2 Prothena Corporation Plc Business Overview
6.4.3 Prothena Corporation Plc Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Prothena Corporation Plc Amyloidosis Therapeutics Product Portfolio
6.4.5 Prothena Corporation Plc Recent Developments
6.5 ProteoTech, Inc.
6.5.1 ProteoTech, Inc. Comapny Information
6.5.2 ProteoTech, Inc. Business Overview
6.5.3 ProteoTech, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.5.4 ProteoTech, Inc. Amyloidosis Therapeutics Product Portfolio
6.5.5 ProteoTech, Inc. Recent Developments
6.6 Onyx Pharmaceuticals, Inc.
6.6.1 Onyx Pharmaceuticals, Inc. Comapny Information
6.6.2 Onyx Pharmaceuticals, Inc. Business Overview
6.6.3 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Onyx Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
6.6.5 Onyx Pharmaceuticals, Inc. Recent Developments
6.7 Millennium Pharmaceuticals, Inc.
6.7.1 Millennium Pharmaceuticals, Inc. Comapny Information
6.7.2 Millennium Pharmaceuticals, Inc. Business Overview
6.7.3 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Millennium Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
6.7.5 Millennium Pharmaceuticals, Inc. Recent Developments
6.8 Isis Pharmaceuticals, Inc.
6.8.1 Isis Pharmaceuticals, Inc. Comapny Information
6.8.2 Isis Pharmaceuticals, Inc. Business Overview
6.8.3 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Isis Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
6.8.5 Isis Pharmaceuticals, Inc. Recent Developments
6.9 Celgene Corporation
6.9.1 Celgene Corporation Comapny Information
6.9.2 Celgene Corporation Business Overview
6.9.3 Celgene Corporation Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Celgene Corporation Amyloidosis Therapeutics Product Portfolio
6.9.5 Celgene Corporation Recent Developments
6.10 Bsim2
6.10.1 Bsim2 Comapny Information
6.10.2 Bsim2 Business Overview
6.10.3 Bsim2 Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Bsim2 Amyloidosis Therapeutics Product Portfolio
6.10.5 Bsim2 Recent Developments
6.11 Bellus Health Inc.
6.11.1 Bellus Health Inc. Comapny Information
6.11.2 Bellus Health Inc. Business Overview
6.11.3 Bellus Health Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Bellus Health Inc. Amyloidosis Therapeutics Product Portfolio
6.11.5 Bellus Health Inc. Recent Developments
6.12 Arcturus Therapeutics, Inc
6.12.1 Arcturus Therapeutics, Inc Comapny Information
6.12.2 Arcturus Therapeutics, Inc Business Overview
6.12.3 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Arcturus Therapeutics, Inc Amyloidosis Therapeutics Product Portfolio
6.12.5 Arcturus Therapeutics, Inc Recent Developments
6.13 Alnylam Pharmaceuticals, Inc.
6.13.1 Alnylam Pharmaceuticals, Inc. Comapny Information
6.13.2 Alnylam Pharmaceuticals, Inc. Business Overview
6.13.3 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Alnylam Pharmaceuticals, Inc. Amyloidosis Therapeutics Product Portfolio
6.13.5 Alnylam Pharmaceuticals, Inc. Recent Developments
7 North America by Country
7.1 North America Amyloidosis Therapeutics Sales by Country
7.1.1 North America Amyloidosis Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.1.2 North America Amyloidosis Therapeutics Sales by Country (2020-2025)
7.1.3 North America Amyloidosis Therapeutics Sales Forecast by Country (2026-2031)
7.2 North America Amyloidosis Therapeutics Market Size by Country
7.2.1 North America Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2.2 North America Amyloidosis Therapeutics Market Size by Country (2020-2025)
7.2.3 North America Amyloidosis Therapeutics Market Size Forecast by Country (2026-2031)
8 Europe by Country
8.1 Europe Amyloidosis Therapeutics Sales by Country
8.1.1 Europe Amyloidosis Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.1.2 Europe Amyloidosis Therapeutics Sales by Country (2020-2025)
8.1.3 Europe Amyloidosis Therapeutics Sales Forecast by Country (2026-2031)
8.2 Europe Amyloidosis Therapeutics Market Size by Country
8.2.1 Europe Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2.2 Europe Amyloidosis Therapeutics Market Size by Country (2020-2025)
8.2.3 Europe Amyloidosis Therapeutics Market Size Forecast by Country (2026-2031)
9 Asia-Pacific by Country
9.1 Asia-Pacific Amyloidosis Therapeutics Sales by Country
9.1.1 Asia-Pacific Amyloidosis Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.1.2 Asia-Pacific Amyloidosis Therapeutics Sales by Country (2020-2025)
9.1.3 Asia-Pacific Amyloidosis Therapeutics Sales Forecast by Country (2026-2031)
9.2 Asia-Pacific Amyloidosis Therapeutics Market Size by Country
9.2.1 Asia-Pacific Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2.2 Asia-Pacific Amyloidosis Therapeutics Market Size by Country (2020-2025)
9.2.3 Asia-Pacific Amyloidosis Therapeutics Market Size Forecast by Country (2026-2031)
10 South America by Country
10.1 South America Amyloidosis Therapeutics Sales by Country
10.1.1 South America Amyloidosis Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.1.2 South America Amyloidosis Therapeutics Sales by Country (2020-2025)
10.1.3 South America Amyloidosis Therapeutics Sales Forecast by Country (2026-2031)
10.2 South America Amyloidosis Therapeutics Market Size by Country
10.2.1 South America Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2.2 South America Amyloidosis Therapeutics Market Size by Country (2020-2025)
10.2.3 South America Amyloidosis Therapeutics Market Size Forecast by Country (2026-2031)
11 Middle East and Africa by Country
11.1 Middle East and Africa Amyloidosis Therapeutics Sales by Country
11.1.1 Middle East and Africa Amyloidosis Therapeutics Sales Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.1.2 Middle East and Africa Amyloidosis Therapeutics Sales by Country (2020-2025)
11.1.3 Middle East and Africa Amyloidosis Therapeutics Sales Forecast by Country (2026-2031)
11.2 Middle East and Africa Amyloidosis Therapeutics Market Size by Country
11.2.1 Middle East and Africa Amyloidosis Therapeutics Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2.2 Middle East and Africa Amyloidosis Therapeutics Market Size by Country (2020-2025)
11.2.3 Middle East and Africa Amyloidosis Therapeutics Market Size Forecast by Country (2026-2031)
12 Value Chain and Sales Channels Analysis
12.1 Amyloidosis Therapeutics Value Chain Analysis
12.1.1 Amyloidosis Therapeutics Key Raw Materials
12.1.2 Key Raw Materials Price
12.1.3 Raw Materials Key Suppliers
12.1.4 Manufacturing Cost Structure
12.1.5 Amyloidosis Therapeutics Production Mode & Process
12.2 Amyloidosis Therapeutics Sales Channels Analysis
12.2.1 Direct Comparison with Distribution Share
12.2.2 Amyloidosis Therapeutics Distributors
12.2.3 Amyloidosis Therapeutics Customers
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.